Liver disease is frequently asymptomatic, challenging early identification in the primary care
setting. The fibrosis 4 (FIB4) index is a liver fibrosis biomarker that is a potential alternative …

Background Alpha-1 antitrypsin deficiency (AATD) is characterized by reduced serum levels
of the AAT protein and predisposes to liver and lung disease. The characterization at …

Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) have been
traditionally linked to one another. Recent studies suggest that NAFLD may be increasingly …

Background & aims HCV CD4+ and CD8+ specific T cells responses are functionally impaired
during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than …

Background SARS-CoV-2 infection portends a broad range of outcomes, from a majority of
asymptomatic cases to a lethal disease. Robust correlates of severe COVID-19 include old …

Nonalcoholic steatohepatitis (NASH) is a leading cause of cirrhosis in western countries.
Insulin resistance (IR), type 2 diabetes (T2D), and the polymorphisms patatin-like …

Predicting disease severity in patients infected with SARS-CoV-2 is difficult. Soluble
angiotensin-converting enzyme 2 (sACE2) arises from the shedding of membrane ACE2 (mACE2), …

Background Alpha-1 antitrypsin deficiency (AATD) is considered one of the most common
genetic diseases and is characterised by the misfolding and polymerisation of the alpha-1 …

Introduction SARS-CoV-2 pneumonia can lead to several sequelae, among them, pulmonary
fibrosis. The Enhanced Liver Fibrosis (ELF) score is a panel of serum markers of liver …

Background and Aims: The prevalence of chronic non-communicable diseases, particularly
metabolic syndrome (MetS), has increased among the prison population. Nevertheless, we …